BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11081455)

  • 1. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.
    Oettle H; Arnold D; Esser M; Huhn D; Riess H
    Anticancer Drugs; 2000 Sep; 11(8):635-8. PubMed ID: 11081455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
    Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.
    Higashiyama T; Ito Y; Hirokawa M; Fukushima M; Uruno T; Miya A; Matsuzuka F; Miyauchi A
    Thyroid; 2010 Jan; 20(1):7-14. PubMed ID: 20025538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
    Rosenberg P; Andersson H; Boman K; Ridderheim M; Sorbe B; Puistola U; Parö G
    Acta Oncol; 2002; 41(5):418-24. PubMed ID: 12442916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.
    Maeda S; Motoi F; Onogawa T; Morikawa T; Shigeru O; Sakata N; Takadate T; Naitoh T; Rikiyama T; Katayose Y; Egawa S; Unno M
    Int J Clin Oncol; 2011 Oct; 16(5):539-45. PubMed ID: 21455624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
    Shukuya T; Yasui H; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
    Jpn J Clin Oncol; 2010 Dec; 40(12):1135-8. PubMed ID: 20656694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12.
    Rich T; Harris J; Abrams R; Erickson B; Doherty M; Paradelo J; Small W; Safran H; Wanebo HJ
    Am J Clin Oncol; 2004 Feb; 27(1):51-6. PubMed ID: 14758134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U; Harstrick A; Wilke H; Seeber S
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer.
    Choy H; Safran H; Akerley W; Graziano SL; Bogart JA; Cole BF
    Clin Cancer Res; 1998 Aug; 4(8):1931-6. PubMed ID: 9717821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activity of paclitaxel in gastrointestinal tumors.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
    Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study.
    Whitehead RP; Jacobson J; Brown TD; Taylor SA; Weiss GR; Macdonald JS
    J Clin Oncol; 1997 Jun; 15(6):2414-9. PubMed ID: 9196157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
    J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
    Choy H; Yee L; Cole BF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.